These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 31182761)
21. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Song EK; Tai WM; Messersmith WA; Bagby S; Purkey A; Quackenbush KS; Pitts TM; Wang G; Blatchford P; Yahn R; Kaplan J; Tan AC; Atreya CE; Eckhardt G; Kelley RK; Venook A; Kwak EL; Ryan D; Arcaroli JJ Int J Cancer; 2015 Apr; 136(8):1967-75. PubMed ID: 25242168 [TBL] [Abstract][Full Text] [Related]
22. Isobavachalcone isolated from Li Y; Qin X; Li P; Zhang H; Lin T; Miao Z; Ma S Drug Des Devel Ther; 2019; 13():1449-1460. PubMed ID: 31118579 [No Abstract] [Full Text] [Related]
23. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062 [TBL] [Abstract][Full Text] [Related]
24. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer. Allen JE; Gallant JN; Dicker DT; Amin S; Irby RB; Sharma AK; El-Deiry WS PLoS One; 2013; 8(3):e59380. PubMed ID: 23555026 [TBL] [Abstract][Full Text] [Related]
25. Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA. Huang Y; Liu N; Liu J; Liu Y; Zhang C; Long S; Luo G; Zhang L; Zhang Y Cell Cycle; 2019 Dec; 18(24):3442-3455. PubMed ID: 31726940 [No Abstract] [Full Text] [Related]
26. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma. Liu Q; Mier JW; Panka DJ Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745 [TBL] [Abstract][Full Text] [Related]
27. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. Ruan M; Liu M; Dong Q; Chen L J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669 [TBL] [Abstract][Full Text] [Related]
28. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179 [TBL] [Abstract][Full Text] [Related]
29. Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway. Xu J; Zhang S; Wang R; Wu X; Zeng L; Fu Z Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28432271 [TBL] [Abstract][Full Text] [Related]
30. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. Takada Y; Fang X; Jamaluddin MS; Boyd DD; Aggarwal BB J Biol Chem; 2004 Sep; 279(38):39541-54. PubMed ID: 15252041 [TBL] [Abstract][Full Text] [Related]
31. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Zhang L; Scorsone K; Woodfield SE; Zage PE Cancer Chemother Pharmacol; 2015 Nov; 76(5):977-87. PubMed ID: 26407819 [TBL] [Abstract][Full Text] [Related]
32. FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction. Wu DW; Lee MC; Hsu NY; Wu TC; Wu JY; Wang YC; Cheng YW; Chen CY; Lee H Oncogene; 2015 May; 34(19):2505-15. PubMed ID: 24998847 [TBL] [Abstract][Full Text] [Related]
33. Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis. Qiu W; Leibowitz B; Zhang L; Yu J Oncogene; 2010 Mar; 29(11):1622-32. PubMed ID: 19966853 [TBL] [Abstract][Full Text] [Related]
34. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB. Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of AKT/FoxO3a signaling induced PUMA expression in response to p53-independent cytotoxic effects of H1: A derivative of tetrandrine. Zhang YX; Liu XM; Wang J; Li J; Liu Y; Zhang H; Yu XW; Wei N Cancer Biol Ther; 2015; 16(6):965-75. PubMed ID: 25893985 [TBL] [Abstract][Full Text] [Related]
36. Upregulation of RGS4 expression by IL-1beta in colonic smooth muscle is enhanced by ERK1/2 and p38 MAPK and inhibited by the PI3K/Akt/GSK3beta pathway. Hu W; Li F; Mahavadi S; Murthy KS Am J Physiol Cell Physiol; 2009 Jun; 296(6):C1310-20. PubMed ID: 19369446 [TBL] [Abstract][Full Text] [Related]
37. Cisplatin induced apoptosis of ovarian cancer A2780s cells by activation of ERK/p53/PUMA signals. Song H; Wei M; Liu W; Shen S; Li J; Wang L Histol Histopathol; 2018 Jan; 33(1):73-79. PubMed ID: 28287251 [TBL] [Abstract][Full Text] [Related]
38. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. Dvory-Sobol H; Sagiv E; Liberman E; Kazanov D; Arber N Cancer; 2007 Jan; 109(2):188-97. PubMed ID: 17149756 [TBL] [Abstract][Full Text] [Related]